Evidence map›Paper›PMID 37755563›Full record

ArticleAnnals of surgical oncology2024

Patterns of Recurrence After Poor Response to Neoadjuvant Chemotherapy in Gastric Cancer and the Role for Adjuvant Radiation.

Caressa Hui, Agnes Ewongwo, Brianna Lau, George Fisher, Daniel Delitto, George Poultsides, Quoc-Anh Ho, Elham Rahimy, Erqi Pollom, Daniel T Chang and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Impact of histologically poorly cohesive phenotype as a prognostic factor in patients with pStage II/III gastric cancer undergoing adjuvant chemotherapy.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025
    Article
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Caressa HuiDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.
Agnes EwongwoDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.
Brianna LauDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.
George FisherDepartment of Medical Oncology, Stanford University, Stanford, CA, USA.
Daniel DelittoDepartment of Medical Oncology, Stanford University, Stanford, CA, USA.
George PoultsidesDepartment of Surgical Oncology, Stanford University, Stanford, CA, USA.
Quoc-Anh HoDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.
Elham RahimyDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.
Erqi PollomDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.
Daniel T ChangDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Lucas K VitzthumDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA. vitzthum@stanford.edu.
Stanford University · USUniversity of Michigan–Ann Arbor · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImproved treatment strategies are needed for patients with locally advanced gastric cancer with poor response to neoadjuvant chemotherapy. We aimed to describe patterns of failure for patients with no or partial response (NR, PR) to preoperative chemotherapy. PATIENTS AND

methodsWe analyzed patients with locally advanced gastric cancer treated from 2008 to 2022 with preoperative chemotherapy followed by surgery with D2 resection. We excluded patients who received radiation. Cumulative incidence of locoregional failure (LRF) and distant metastases (DM) were calculated. For patients with recurrent abdominal disease, hypothetical radiation clinical treatment volumes (CTV) were contoured on postoperative scans and compared with patterns of recurrence.

resultsA total of 60 patients were identified. The most used preoperative chemotherapy was FLOT (38.6%), followed by FOLFOX (30%) and ECF/ECX/EOX (23.3%). Four (6.7%), 40 (66.7%), and 9 patients (15%) had a complete pathologic response (CR), PR, and NR to neoadjuvant therapy, respectively. Among patients without a CR, 3-year overall and progression-free survival rates were 62.3% (95% CI 48-76.6%) and 51.3% (95% CI 36.9-65.7%), respectively. Three-year cumulative incidence of LRF and DM were 8.4% (95% CI 0.4-16.4%) and 41.0% (95% CI 26.3-55.4%), respectively. Absolute rates of patients having the first site of recurrence encompassed by a postoperative radiation CTV was 2.0% for patients without a CR and 0% for patients with NR.

conclusionsPatients with locally advanced gastric cancer with less than a CR to chemotherapy have poor outcomes due to high rates of DM. Adjuvant locoregional therapy such as radiation is unlikely to affect survival.

Indexed as

Stomach NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantCombined Modality TherapyHumansNeoadjuvant TherapyNeoplasm StagingRadiotherapy, AdjuvantChemotherapyD2 resectionGastric cancerRadiation

Identifiers

PMID37755563
OpenAlexW4387077778

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.